A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Completed
Seagen Inc.
Phase 1
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory
B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage
lymphoblastic lymphoma (B-LBL).
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Completed
Seattle Genetics, Inc.
Phase 1
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory
B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage
lymphoblastic lymphoma (B-LBL).
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin
lymphoma (B-NHL)
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin
lymphoma (B-NHL)
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Terminated
Seagen Inc.
Phase 2
The purpose of this randomized, open-label study is to evaluate the safety and efficacy of
denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when
compared to RICE alone in the treatment of patients with relapsed or refractory diffuse large
B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also be
candidates for autologous stem cell transplant. Patients will be randomly assigned in a 1:1
ratio to receive 3 cycles of study treatment with either denintuzumab mafodotin + RICE or
RICE alone. The study will assess whether there is a difference between the 2 groups in the
side effects that are reported and the number of patients who achieve complete remission at
the end of their study treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
